MA40589A - Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines - Google Patents

Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines

Info

Publication number
MA40589A
MA40589A MA040589A MA40589A MA40589A MA 40589 A MA40589 A MA 40589A MA 040589 A MA040589 A MA 040589A MA 40589 A MA40589 A MA 40589A MA 40589 A MA40589 A MA 40589A
Authority
MA
Morocco
Prior art keywords
progenitor cells
frizzled
jagged
ventricular progenitor
ventricular
Prior art date
Application number
MA040589A
Other languages
English (en)
Inventor
Kenneth R Chien
Xiaojun Lian
Original Assignee
Procella Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procella Therapeutics Ab filed Critical Procella Therapeutics Ab
Publication of MA40589A publication Critical patent/MA40589A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne jagged 1 et frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiomyogènes humaines, en particulier des cellules progénitrices qui se différencient préférentiellement en cellules musculaires ventriculaires cardiaques. Par conséquent, l'invention concerne des cellules progénitrices ventriculaires humaines (hvp), et des procédés de séparation in vitro de cellules progénitrices ventriculaires islet 1+/jagged 1+ et/ou de cellules progénitrices ventriculaires islet1+/frizzled 4+ et/ou de cellules progénitrices ventriculaires islet 1+/jagged 1+/frizzled 4+, et leur expansion et propagation à grande échelle. D'importantes populations clonales de cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ isolées sont également décrites. L'invention concerne également des procédés d'utilisation in vivo des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour la réparation cardiaque ou pour l'amélioration de la fonction cardiaque. Des procédés d'utilisation des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour le criblage de toxicité cardiaque de composés d'essai sont également décrits.
MA040589A 2014-08-22 2015-08-21 Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines MA40589A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040892P 2014-08-22 2014-08-22
US201562194016P 2015-07-17 2015-07-17

Publications (1)

Publication Number Publication Date
MA40589A true MA40589A (fr) 2017-06-28

Family

ID=54062813

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040589A MA40589A (fr) 2014-08-22 2015-08-21 Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines

Country Status (6)

Country Link
US (1) US10597637B2 (fr)
EP (2) EP3183337B1 (fr)
JP (2) JP6738808B2 (fr)
DK (1) DK3183337T3 (fr)
MA (1) MA40589A (fr)
WO (1) WO2016029122A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3183337B1 (fr) 2014-08-22 2019-02-06 Procella Therapeutics AB Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
FI3417073T3 (fi) * 2016-02-19 2023-11-01 Procella Therapeutics Ab Geenimarkkereita humaanien sydämen kammion progenitorisolujen siirtämiselle
WO2017192606A1 (fr) * 2016-05-02 2017-11-09 Emory University Procédés de production de cellules de type cardiaque spécialisées à partir de cellules souches
US10508263B2 (en) * 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CA3072579A1 (fr) * 2017-08-23 2019-02-28 Procella Therapeutics Ab Utilisation de neuropiline-1 (nrp1) en tant que marqueur de surface cellulaire pour isoler des cellules progenitrices ventriculaires cardiaques humaines
CN109189051A (zh) * 2018-10-29 2019-01-11 江苏罗思韦尔电气有限公司 一种基于T-Box的故障存储及处理方法
WO2023278382A1 (fr) 2021-06-29 2023-01-05 Staffan Holmin Canule d'administration endoluminale
CA3231501A1 (fr) * 2021-09-13 2023-03-16 Steven Kattman Procedes de production de cellules progenitrices cardiaques engagees
WO2023199113A1 (fr) 2022-04-15 2023-10-19 Smartcella Solutions Ab Compositions et procédés d'administration à médiation par des exosomes d'agents d'arnm

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5561384A (en) 1995-11-08 1996-10-01 Advanced Micro Devices, Inc. Input/output driver circuit for isolating with minimal power consumption a peripheral component from a core section
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US7166280B2 (en) 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
EP1435977A4 (fr) 2001-09-19 2005-06-08 Ford Henry Health System Transplantation cardiaque de cellules souches pour le traitement de l'insuffisance cardiaque
WO2004070013A2 (fr) 2003-01-31 2004-08-19 The Regents Of The University Of California Utilisation de l'ilot 1 comme marqueur pour isoler ou produire des cellules souches
US20080038229A1 (en) 2006-08-08 2008-02-14 Minguell Jose J Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium
US20100166714A1 (en) 2006-11-02 2010-07-01 The General Hospital Corporation Cardiovascular stem cells, methods for stem cell isolation, and uses thereof
EP2087098A4 (fr) 2006-11-09 2010-03-31 Univ Johns Hopkins Dedifferenciation de cardiomyocytes mammaliens adultes en cellules souches cardiaques
US20080182328A1 (en) 2006-12-19 2008-07-31 The Burnham Institute Mammalian extraembryonic endoderm cells and methods of isolation
JP2010517578A (ja) 2007-02-09 2010-05-27 ザ ジェネラル ホスピタル コーポレイション Ｉｓｌｅｔ１＋系統に入るように細胞を誘導する方法およびそれを拡大する方法
WO2009017460A1 (fr) 2007-07-31 2009-02-05 Es Cell International Pte Ltd Procédé d'identification et de sélection de cardiomyocytes
CA2743701A1 (fr) * 2007-11-30 2009-06-11 New York Medical College Compositions comprenant des inhibiteurs hdac et procedes permettant de les utiliser pour reparer la fonction des cellules souches et empecher l'insuffisance cardiaque
US20120027807A1 (en) * 2008-10-09 2012-02-02 The General Hospital Corporation Tissue engineered myocardium and methods of production and uses thereof
EP2529008A1 (fr) * 2010-01-26 2012-12-05 Université Libre de Bruxelles Outils pour isoler et suivre des cellules progénitrices cardiovasculaires
US20130209415A1 (en) * 2010-06-03 2013-08-15 The Board Of Trustees Of The Leland Stanford Junior University Purified compositions of cardiovascular progenitor cells
US20120009158A1 (en) * 2010-06-18 2012-01-12 The General Hospital Corporation VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF
WO2012070014A2 (fr) 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification de nouveaux marqueurs de surface cellulaire pour des cellules progénitrices pancréatiques et des cellules endodermiques définies
WO2012162741A1 (fr) * 2011-06-01 2012-12-06 Monash University Enrichissement de cardiomyocytes
WO2013056072A1 (fr) * 2011-10-13 2013-04-18 Wisconsin Alumni Research Foundation Génération de cardiomyocytes à partir de cellules souches pluripotentes humaines
JP5920741B2 (ja) 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
US9234176B2 (en) * 2012-11-13 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Chemically defined production of cardiomyocytes from pluripotent stem cells
EP2968416A4 (fr) 2013-03-15 2016-08-17 Fate Therapeutics Inc Essai d'activité biologique de cellules pour un potentiel thérapeutique
US10888588B2 (en) 2013-10-18 2021-01-12 Icahn School Of Medicine At Mount Sinai Directed cardiomyocyte differentiation and ventricular specification of stem cells
ES2689804T3 (es) 2013-11-20 2018-11-15 Miltenyi Biotec Gmbh Composiciones de subpoblaciones de cardiomiocitos
JP6571115B2 (ja) * 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
EP3138906B1 (fr) * 2014-05-01 2019-08-21 iHeart Japan Corporation Cellules progénitrices cardiaques positives pour le cd82
EP3183337B1 (fr) 2014-08-22 2019-02-06 Procella Therapeutics AB Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
JP2018510649A (ja) 2015-02-17 2018-04-19 ユニバーシティー ヘルス ネットワーク 洞房結節様ペースメーカー心筋細胞および心室様心筋細胞を作製および使用するための方法
FI3417073T3 (fi) 2016-02-19 2023-11-01 Procella Therapeutics Ab Geenimarkkereita humaanien sydämen kammion progenitorisolujen siirtämiselle
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells

Also Published As

Publication number Publication date
EP3183337A1 (fr) 2017-06-28
JP6738808B2 (ja) 2020-08-12
JP2020120677A (ja) 2020-08-13
DK3183337T3 (en) 2019-04-01
US20160053229A1 (en) 2016-02-25
US10597637B2 (en) 2020-03-24
EP3183337B1 (fr) 2019-02-06
JP2017525393A (ja) 2017-09-07
WO2016029122A1 (fr) 2016-02-25
EP3524673A1 (fr) 2019-08-14

Similar Documents

Publication Publication Date Title
MA40589A (fr) Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
EA201290527A1 (ru) Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EP3388512A4 (fr) Procédé de séparation et de culture de cellules souches mésenchymateuses à partir de tissu de la gelée de wharton de cordon ombilical
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
EP4368728A3 (fr) Quantification simultanée de l'expression génique dans une région définie par l'utilisateur d'un tissu en coupe transversale
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
PH12016502012A1 (en) Defined composition gene modified t-cell products
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EP4292600A3 (fr) Photorécepteurs et progéniteurs de photorécepteurs produits à partir de cellules souches pluripotentes
WO2015154012A8 (fr) Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations
CA3011049A1 (fr) Compositions pour lier des domaines de liaison a l'adn et des domaines de clivage
EA201790357A1 (ru) Способ получения клеток-предшественников зрелой печени
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
PH12014502508B1 (en) hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2015181831A3 (fr) Procédé pour cibler un glioblastome avec des cellules souches mésenchymateuses de la gelée de wharton (cms-gw) dérivées de cordon ombilical humain
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
MX2016016756A (es) Terapia con células madre en patologías endometriales.
WO2006102209A3 (fr) Cellules cd34(+) et leurs procedes d'utilisation
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
WO2018140850A3 (fr) Lymphocytes t dérivés de sang de cordon ombilical
MX2022001694A (es) Metodos y composiciones para mejorar el rendimiento de soya.